Sanofi has completed its acquisition of Blueprint Medicines, enhancing its portfolio with a commercialised therapy and the ...

Paris: Sanofi has announced the completion of its acquisition of Blueprint Medicines Corporation, adding to its portfolio a ...

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its ...

Sanofi acquires Vicebio for $1.15 billion, adding a next-gen RSV-hMPV vaccine and ‘Molecular Clamp' tech to strengthen its respiratory vaccine pipeline.

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation ( ...

Pharmaceutical manufacturing in the U.S. has declined sharply over recent decades, with most active ingredient production ...

The targeted cancer drug specialist has sold its interest in tyrosine kinase inhibitor Ayvakit/Ayvakyt (avapritinib) and Roche-partnered RET inhibitor Gavreto (pralsetinib) in two separate ...